Scarica l'app Stockscreener
3.00
1.64%
-0.05
Dopo l'orario di chiusura:
3.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NMRA Giù?
Forum
Previsione
Precedente Chiudi:
$3.05
Aprire:
$3.09
Volume 24 ore:
810.21K
Relative Volume:
0.52
Capitalizzazione di mercato:
$509.82M
Reddito:
-
Utile/perdita netta:
$-236.30M
Rapporto P/E:
-2.0502
EPS:
-1.4633
Flusso di cassa netto:
$-208.07M
1 W Prestazione:
-15.49%
1M Prestazione:
+53.06%
6M Prestazione:
+78.57%
1 anno Prestazione:
+109.79%
Intervallo 1D:
$2.915
$3.09
Intervallo di 1 settimana:
$2.76
$3.60
Portata 52W:
$0.611
$3.65
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Nome
Neumora Therapeutics Inc
Settore
Industria
Telefono
(857) 760-0900
Indirizzo
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Compare NMRA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
3.00 | 518.31M | 0 | -236.30M | -208.07M | -1.4633 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-17 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2026-01-12 | Iniziato | Leerink Partners | Outperform |
| 2025-12-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-27 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-09-16 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-04-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2025-03-10 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-07 | Downgrade | Stifel | Buy → Hold |
| 2025-01-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-07-08 | Iniziato | Mizuho | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Hold |
| 2023-10-10 | Iniziato | BofA Securities | Buy |
| 2023-10-10 | Iniziato | Guggenheim | Buy |
| 2023-10-10 | Iniziato | JP Morgan | Overweight |
| 2023-10-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-10-10 | Iniziato | Stifel | Buy |
| 2023-10-10 | Iniziato | William Blair | Outperform |
Mostra tutto
Neumora Therapeutics Inc Borsa (NMRA) Ultime notizie
Neumora Therapeutics Inc (NMRA) Sheds More Light on Phase 1b Study of NMRA-511 - Finviz
Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic Agreements - Bitget
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
12 Best NASDAQ Penny Stocks to Buy According to Analysts - Insider Monkey
Neumora Therapeutics (NASDAQ:NMRA) Shares Gap DownTime to Sell? - MarketBeat
GSA Capital Partners LLP Cuts Position in Neumora Therapeutics, Inc. $NMRA - MarketBeat
AlphaCore Capital LLC Has $1.16 Million Stock Holdings in Neumora Therapeutics, Inc. $NMRA - MarketBeat
Neumora Therapeutics (NMRA) Projected to Post Earnings on Monday - MarketBeat
Neumora cut to Hold at Stifel after J&J’s VENTURA exit - MSN
Can Neumora Therapeutics Inc. stock withstand economic slowdownJuly 2025 Snapshot & Weekly Setup with High ROI Potential - mfd.ru
Risk Recap: Is Telomir Pharmaceuticals Inc stock a buy or sellFed Meeting & Smart Allocation Stock Tips - baoquankhu1.vn
Neumora Therapeutics CFO Milligan sells $5119 in shares By Investing.com - Investing.com Australia
Neumora Therapeutics CFO Milligan sells $5119 in shares - Investing.com South Africa
Top Neumora Executives Quietly Cash Out in Coordinated Stock Sell-Off - TipRanks
Insider Sell Alert: Michael Milligan Sells Shares of Neumora The - GuruFocus
Neumora Therapeutics (NASDAQ:NMRA) Insider Paul Berns Sells 9,819 Shares - MarketBeat
Insider Selling: Neumora Therapeutics (NASDAQ:NMRA) Insider Sells 6,165 Shares of Stock - MarketBeat
Trading Recap: Will Neumora Therapeutics Inc stock go up in YEARTake Profit & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Neumora Therapeutics advances in novel brain-penetrant therapies - Traders Union
Neumora Therapeutics (NASDAQ:NMRA) Hits New 12-Month High Following Analyst Upgrade - MarketBeat
William Blair upgrades Neumora Therapeutics (NMRA) - MSN
William Blair Upgrades Neumora Therapeutics (NMRA) - Nasdaq
Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment - Benzinga
Neumora Therapeutics Shares Rise After William Blair Upgrade - marketscreener.com
Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Up After Analyst Upgrade - MarketBeat
William Blair Upgrades Neumora Therapeutics to Outperform From Market Perform - marketscreener.com
Neumora Therapeutics (NASDAQ:NMRA) Rating Increased to Outperform at William Blair - MarketBeat
Will Neumora Therapeutics Inc. stock go up in YEAR2025 Trading Recap & Fast Entry Momentum Trade Alerts - mfd.ru
Neumora Therapeutics Highlights NMRA-511 AD Agitation Signal, Maps Higher-Dose Plan for 2026 - MarketBeat
NMRA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Neumora Therapeutics (NASDAQ:NMRA) Sets New 1-Year HighHere's What Happened - MarketBeat
Neumora Therapeutics, Inc. (NMRA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026Slideshow (NASDAQ:NMRA) 2026-02-12 - Seeking Alpha
NMRA: NMRA-511 shows strong efficacy in Alzheimer's agitation; pipeline and cash runway support growth - TradingView
Differentiated NMRA-511 Efficacy and Safety in Alzheimer’s Agitation Support Buy Rating on Neumora - TipRanks
Does Neumora Therapeutics’ (NMRA) Guggenheim Spotlight Recast Its Core Neuroscience Investment Narrative? - simplywall.st
Neumora Therapeutics, Inc. Presents NMRA-511 Efficacy at Biotech Summit - TradingView
Neumora Therapeutics (NASDAQ:NMRA) Trading Up 25.3%What's Next? - MarketBeat
3 Promising Penny Stocks With Market Caps Up To $400M - simplywall.st
Neumora gains after early-stage trial results for Alzheimer’s product - MSN
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Hold" by Analysts - MarketBeat
Resistance Check: Should I buy Neumora Therapeutics Inc stock nowPortfolio Update Report & Expert Verified Movement Alerts - baoquankhu1.vn
Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Short Interest in Neumora Therapeutics, Inc. (NASDAQ:NMRA) Drops By 20.2% - MarketBeat
ETF Watch: Will Neumora Therapeutics Inc stock go up in YEAR2025 Earnings Surprises & Consistent Return Investment Signals - baoquankhu1.vn
FY2030 Earnings Estimate for NMRA Issued By HC Wainwright - MarketBeat
Stop Loss: Can QMMM Holdings Limited navigate macro headwindsQuarterly Market Review & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Investment Review: What makes SZZLU stock attractive todayInflation Watch & Weekly High Return Forecasts - baoquankhu1.vn
NMRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Targets Report: Can AZEK continue delivering strong returnsQuarterly Profit Report & AI Based Trade Execution Alerts - baoquankhu1.vn
Volume Report: Is Neumora Therapeutics Inc showing insider buying2025 Fundamental Recap & Weekly Return Optimization Alerts - baoquankhu1.vn
Earnings Beat: Should I hold or sell SPCE nowMarket Weekly Review & Fast Gain Stock Trading Tips - baoquankhu1.vn
Neumora Therapeutics Inc Azioni (NMRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Neumora Therapeutics Inc Azioni (NMRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Pinto Joshua | President |
Feb 17 '26 |
Sale |
3.54 |
5,967 |
21,093 |
57,783 |
| BERNS PAUL L | See Remarks |
Feb 17 '26 |
Sale |
3.51 |
9,819 |
34,459 |
7,395,185 |
| Milligan Michael Lee | See Remarks |
Feb 17 '26 |
Sale |
3.56 |
1,436 |
5,119 |
21,034 |
3.69%
0.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):